ESMO PRECEPTORSHIP PROGRAMME
SUPPORTIVE AND PALLIATIVE CARE

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Lugano, Switzerland
30-31 March 2023

**CO-CHAIRS:** Christina Ruhlmann, Denmark
Florian Scotté, France

**SPEAKERS:** Jann Arends, Germany
Snežana Bosnjak, Serbia
Maria Die Trill, Spain
Karin Jordan, Germany
Anne Letsch, Germany
Jayne Wood, United Kingdom

**LEARNING OBJECTIVES**

- Understand mechanisms, risk, prevention and treatment of the key symptoms and syndromes pain, anorexia, cachexia, dyspnea, nausea, vomiting, diarrhea, constipation, mucositis, neurotoxicity, cardiovascular events, venous thromboembolism, hematological complications and their association with cancer disease and antineoplastic treatment.
- Understand integration of screening for and assessment of toxicities to antineoplastic treatment, symptoms and other supportive and palliative care needs, and integration of their management in routine oncology care.
- Understand the role of rehabilitation in the continuum of supportive care.
- Describe required competences of multidisciplinary and inter-professional teams for multimodal management.
- Understand key steps to prepare patients and family members for end-of-life and care of the dying person.
- Understand how to communicate with patients about illness, prognosis, coping, hope and decisions. Reflect on your own role and how to address cultural differences.
- Get familiar with the ESMO Clinical Practice Guidelines on supportive and palliative care topics.

**Thursday, 30 March**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
<th>09:00-10:20 80'</th>
<th>Overview of main issues of supportive and palliative care</th>
<th>Chairs: Christina Ruhlmann, DK Florian Scotté, FR</th>
</tr>
</thead>
<tbody>
<tr>
<td>10'</td>
<td>Welcome</td>
<td></td>
<td>Welcome and Introduction—Goals of the preceptorship, learning objectives, and the ESMO/ASCO Global Curriculum in Medical Oncology</td>
<td>Christina Ruhlmann, DK</td>
</tr>
<tr>
<td>15'</td>
<td>ESMO</td>
<td></td>
<td>ESMO Clinical Practice Guidelines on Supportive and Palliative Care: What’s old, what’s new, and what’s to expect for the future?</td>
<td>Florian Scotté, FR</td>
</tr>
<tr>
<td>5'</td>
<td>Q&amp;A</td>
<td></td>
<td>Q&amp;A</td>
<td>Florian Scotté, FR</td>
</tr>
<tr>
<td>15'</td>
<td>Rehabilitation</td>
<td></td>
<td>Rehabilitation: An emerging integral part of supportive and palliative care</td>
<td>Jann Arends, DE</td>
</tr>
<tr>
<td>5'</td>
<td>Q&amp;A</td>
<td></td>
<td>Q&amp;A</td>
<td>Jann Arends, DE</td>
</tr>
<tr>
<td>15'</td>
<td>Communication</td>
<td></td>
<td>Communication with cancer patients: Challenging situations, breaking bad news, family perspectives, desire to hasten death</td>
<td>Maria Die Trill, ES</td>
</tr>
<tr>
<td>5'</td>
<td>Q&amp;A</td>
<td></td>
<td>Q&amp;A</td>
<td>Maria Die Trill, ES</td>
</tr>
<tr>
<td>10'</td>
<td>Participant</td>
<td></td>
<td>Participant clinical case and discussion (1x10')</td>
<td>Faculty</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Chair</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:20-10:50</td>
<td>Coffee break</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 10:50-12:25 | SESSION 2  
Prevention and treatment of complications, toxicities and symptoms | Chair: Jayne Wood, UK                       |
| 20’       | Chemotherapy-induced peripheral neuropathy: Mechanism, prevention and treatment | Karin Jordan, DE                          |
| 5’        | Q&A                                                                      | Karin Jordan, DE                          |
| 20’       | Medical management of cancer pain and other complex symptom control      | Jayne Wood, UK                             |
| 5’        | Q&A                                                                      | Jayne Wood, UK                             |
| 20’       | Interventional management of cancer pain and other complex symptom control | Maria Die Trill, ES                        |
| 5’        | Q&A                                                                      | Maria Die Trill, ES                        |
| 10’       | Participant clinical case and discussion (1x10’)                         | Faculty                                    |
| 10’       | Participant clinical case and discussion (1x10’)                         | Faculty                                    |
| 12:25-13:25 | Lunch                                                                   |                                            |
| 13:25-14:50 | SESSION 3  
Cardiovascular toxicity, cancer associated thrombosis | Chair: Christina Ruhlmann, DK               |
| 20’       | Extravasation of anticancer agents including when to call the surgeon    | Karin Jordan, DE                          |
| 5’        | Q&A                                                                      | Karin Jordan, DE                          |
| 20’       | Cancer associated venous thromboembolism: Mechanism and management       | Christina Ruhlmann, DK                     |
| 5’        | Q&A                                                                      | Christina Ruhlmann, DK                     |
| 20’       | Acute and late cardiovascular toxicity induced by anti-tumour therapy    | Karin Jordan, DE                          |
| 5’        | Q&A                                                                      | Karin Jordan, DE                          |
| 10’       | Participant clinical case and discussion (1x10’)                         | Faculty                                    |
| 14:50-16:05 | SESSION 4  
Digestive tract symptoms and toxicity                              | Chair: Karin Jordan, DE                    |
| 15’       | Anticancer therapy-induced diarrhoea: Prevention and management strategies | Florian Scotté, FR                         |
| 15’       | Anticancer therapy-induced oral mucositis: Prevention and management strategies | Florian Scotté, FR                         |
| 5’        | Q&A                                                                      | Florian Scotté, FR                         |
| 10’       | Participant clinical case and discussion (1x10’)                         | Faculty                                    |
| 15’       | Constipation in advanced cancer                                          | Snežana Bosnjak, RS                        |
| 5’        | Q&A                                                                      | Snežana Bosnjak, RS                        |
| 10’       | Participant clinical case and discussion (1x10’)                         | Faculty                                    |
| 16:05-16:35 | Coffee break                                                            |                                            |
| 16:35-18:15 | SESSION 5  
Digestive tract symptoms and toxicity - Continued                | Chair: Florian Scotté, FR                  |
<p>| 20’       | Prevention and management of cancer disease and chemo- and radiotherapy-induced nausea and vomiting guidelines update and future directions | Snežana Bosnjak, RS                        |
| 5’        | Q&amp;A                                                                      | Snežana Bosnjak, RS                        |
| 15’       | CINV: real life management                                               | Christina Ruhlmann, DK                     |
| 5’        | Q&amp;A                                                                      | Christina Ruhlmann, DK                     |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>20’</td>
<td>Cancer cachexia: Practical assessment, prevention and treatment, including indication for invasive nutrition indicated</td>
<td>Jann Arends, DE</td>
</tr>
<tr>
<td>5’</td>
<td>Q&amp;A</td>
<td>Jann Arends, DE</td>
</tr>
<tr>
<td>20’</td>
<td>Fasting, diets, probiotics, phytotherapy and other Complementary and Alternative Medicine (CAM) issues in practice: When and how to include CAM specialists</td>
<td>Jann Arends, DE</td>
</tr>
<tr>
<td>5’</td>
<td>Q&amp;A</td>
<td>Jann Arends, DE</td>
</tr>
<tr>
<td>5’</td>
<td>Closing remarks Day 1</td>
<td>Florian Scotté, FR</td>
</tr>
</tbody>
</table>

**19:30**  
Dinner

---

**Friday, 31 March**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
</tr>
</thead>
</table>
| 08:30-09:15 | SESSION 6  
Hematological Toxicities | Chair: Christina Ruhlmann, DK |
| 10’    | Anemia: Management evolution from chemotherapy to personalised medicine | Anne Letsch, DE                |
| 5’     | Q&A                                                                     | Anne Letsch, DE                |
| 10’    | Neutropenia – febrile neutropenia: Still a problem?                    | Florian Scotté, FR             |
| 5’     | Q&A                                                                     | Florian Scotté, FR             |
| 10’    | Management of thrombopenia anticancer treatment related                | Anne Letsch, DE                |
| 5’     | Q&A                                                                     | Anne Letsch, DE                |

| Time   | SESSION 7  
Early Palliative Care | Chair: María Die Trill, ES |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>09:15-10:30</td>
<td>Early integration of palliative care across different care settings and professions</td>
<td>Jayne Wood, UK</td>
</tr>
<tr>
<td>5’</td>
<td>Q&amp;A</td>
<td>Jayne Wood, UK</td>
</tr>
<tr>
<td>20’</td>
<td>Care at the end of life: Basic knowledge for the oncologist</td>
<td>Jayne Wood, UK</td>
</tr>
<tr>
<td>5’</td>
<td>Q&amp;A</td>
<td>Jayne Wood, UK</td>
</tr>
<tr>
<td>15’</td>
<td>Breathlessness: From oxygen to sedation</td>
<td>María Die Trill, ES</td>
</tr>
<tr>
<td>5’</td>
<td>Q&amp;A</td>
<td>María Die Trill, ES</td>
</tr>
<tr>
<td>10’</td>
<td>Participant clinical case and discussion (1x10’)</td>
<td>Faculty</td>
</tr>
</tbody>
</table>

**10:30-11:00**  
Coffee break

| Time   | SESSION 8  
Patient Care: Burning questions | Chair: Florian Scotté, FR |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-12:50</td>
<td>Management of toxicities from immunotherapy</td>
<td>Christina Ruhlmann, DK</td>
</tr>
<tr>
<td>5’</td>
<td>Q&amp;A</td>
<td>Christina Ruhlmann, DK</td>
</tr>
<tr>
<td>20’</td>
<td>Patient Remote Monitoring: From trials to guidelines</td>
<td>Anne Letsch, DE</td>
</tr>
<tr>
<td>5’</td>
<td>Q&amp;A</td>
<td>Anne Letsch, DE</td>
</tr>
<tr>
<td>20’</td>
<td>Care Access: How to deal with guidelines</td>
<td>Snezana Bosnjak, RS</td>
</tr>
<tr>
<td>5’</td>
<td>Q&amp;A</td>
<td>Snezana Bosnjak, RS</td>
</tr>
<tr>
<td>Time</td>
<td>Activity</td>
<td>Presenter/Leader</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>15’</td>
<td>What did we learn? – What did we miss?</td>
<td>Christina Ruhlmann, DK</td>
</tr>
<tr>
<td>10’</td>
<td>Participant clinical case and discussion (1x10’)</td>
<td>Faculty</td>
</tr>
<tr>
<td>10’</td>
<td>Participant clinical case and discussion (1x10’)</td>
<td>Faculty</td>
</tr>
<tr>
<td>12:50-13:00</td>
<td>Conclusion, evaluation, and farewell</td>
<td>Christina Ruhlmann, DK Floran Scotte, FR</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Each 10 minute slot for participant clinical case discussion includes 5’ case presentation and 5’ Q&A discussion.